|aValuation techniques :|bdiscounted cash flow, earnings quality, measures of value added, and real options /|cDavid T. Larrabee, [editor], Jason A. Voss, [editor].
|aHoboken, N.J. :|bJohn Wiley & Sons,|cc2013.
|ax, 608 p. ;|c26 cm.
|aCFA Institute investment perspectives series
|aIncludes bibliographical references and index.
|aTwo illustrative approaches to formula valuations of common stocks / Benjamin Graham -- Seeking a margin of safety and valuation / Matthew B. McLennan -- Company performance and measures of value added / Pamela P. Peterson and David R. Peterson -- The affordable dividend approach to equity valuation / Alfred Rappaport -- Discounted-cash-flow approach to valuation / Gregory A. Gilbert -- Equity securities analysis case study : Merck & Company / Randall S. Billingsley -- Traditional equity valuation methods / Thomas A. Martin Jr. -- A simple valuation model and growth expectations / Morris G. Danielson -- Franchise valuation under Q-type competition / Martin L. Leibowitz -- Value enhancement and cash-driven valuation models / Aswath Damodaran -- FEVA : a financial and economic approach to valuation / Xavier Adserà and Pere Viñolas -- Choosing the right valuation approach / Charles M.C. Lee -- Choosing the right valuation approach / Robert Parrino -- Valuing illiquid common stock / Edward A. Dyl and George J. Jiang -- Earnings : measurement, disclosure, and the impact on equity valuation / D. Eric Hirst and Patrick E. Hopkins -- Cash flow analysis and equity valuation / James A. Ohlson -- Accounting valuation : is earnings quality an issue? / Bradford Cornell and Wayne R. Landsman -- Earnings quality analysis and equity valuation / Richard G. Sloan -- Is cash flow king in valuations? / Jing Liu, Doron Nissim, and Jacob Thomas -- Employee stock options and equity valuation / Mark Lang -- Employee stock options valuation with an early exercise boundary / Neil Brisley and Chris K. Anderson -- Real options and investment valuation / Don M. Chance and Pamela P. Peterson -- Real-options valuation for a biotechnology company / David Kellogg and John M. Charnes.